Crispr Therapeutics: A Catalyst-Rich 12 Months Ahead
We bridge the gap between financial information and actionable insight by providing unrivaled coverage on all asset classes and access to best-in-class tools. Invest.","telephone":"+1-347-509-6837","url":"https://seekingalpha.com"},"datePublished":"2026-07-21T06:02:08.000Z","dateModified":"2026-07-21T06:06:37.000Z","description":"CRISPR Therapeutics offers a diversified gene-editing pipeline, with CASGEVY as its lead asset and multiple upcoming catalysts. CRISPR also has two approved therapies, one for Exagamglogene Autotemcel for sickle cell diseaseThis article was written byMax Arnoldi48 FollowersFollowMax is an independent equity research analyst with a primary focus on biotechnology, healthcare, and technology companies.
- ▪We bridge the gap between financial information and actionable insight by providing unrivaled coverage on all asset classes and access to best-in-class tools.
- ▪Invest.","telephone":"+1-347-509-6837","url":"https://seekingalpha.com"},"datePublished":"2026-07-21T06:02:08.000Z","dateModified":"2026-07-21T06:06:37.000Z","description":"CRISPR Therapeutics offers a diversified gene-editing pipeline, wit
- ▪CRISPR also has two approved therapies, one for Exagamglogene Autotemcel for sickle cell diseaseThis article was written byMax Arnoldi48 FollowersFollowMax is an independent equity research analyst with a primary focus on biotechnology, hea
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"Long Ideas","item":"https://seekingalpha.com/stock-ideas/long-ideas"},{"@type":"ListItem","position":4,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4923617-crispr-therapeutics-a-catalyst-rich-12-months-ahead"},"author":{"@type":"Person","name":"Max…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
